INFORMATION DISCLOSURE CITATION OTPE (Use several sheets if necessary)				Attorney Docket 056291-5202		Application No. 10/530,566	
				Applicants: Alan BARGE		P	AGE 1 of 1
OCT 2 1 7005 PTO Form 1449			I. A. Filing Date: October 6, 2003		Group Art Unit: Unassigned		
	reun A	# <i>)</i>	U.S. PA	TENT DOCUMENTS			
Initial	me/	Document No.	Date	Name	Class	Sub-Class	Filing Date
IR.O.	1.	US 6,423,753	July 23, 2002	Dougherty	514	719	January 5, 2000
/K.C./	2.	US 20030055024	March 20, 2003		514	114	September 26, 2002
/K.C./	3.	US 20030166617	September 4, 200		514	114	April 4, 2003
		1	FOREIGN	PATENT DOCUMENTS			
	Γ	Document No.	Date	Country	Class	Sub-Class	Translation
/K.G./	4	WO 99/02166	January 21, 1999		Ciass	Suo-Ciass	A I MIISTALIOL
/K.C./		WO 00/48591	August 24, 2000			-	
		WO 00/48551 WO 01/32651	May 10, 2001	WIPO	+	1	
/K.C./ /K.C./	7	WO 01/74360	October 11, 200		+-	1	
/K.C./	8	WO 01/74360	October 11, 200		+		
/K.C.		WO 02/56692	July 25, 2002	WIPO			
/K.C.		WO 03/088971	October 30, 2002		+-		
	1	110 03.0007.1	00,000, 50, 50.	"""			
		1					
		OTHER DO	OCUMENTS (Inclu	ding Author Title Date De			
	144				rtinent Pa	ges, etc.)	
/K.C	V	Clin. Cancer Res. 8: 1	Antitumor Activity of 974-1983	f the Novel Vascular Targetin	g Agent Z	D6126 in a P	
/K.C.	V	Clin. Cancer Res. 8: 1 Bruns et al. (2002) "V metastasis following o	Antitumor Activity of 974-1983 ascular-targeting action orthotopic tumour cel	f the Novel Vascular Targetin ivity of ZD6126 against prima I injection in a nude mouse m	g Agent Z	D6126 in a P	rowth and lymph node
	V	Clin. Cancer Res. 8: 1: Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "	Antitumor Activity of 974-1983 ascular-targeting action orthotopic tumour cel and Cancer Therapeu The development of	f the Novel Vascular Targetin ivity of ZD6126 against prima I injection in a nude mouse m	ary pancrea odel" 14th	D6126 in a P atic tumour g EORTC-NC	rowth and lymph node I-AACR Symposium
/K.C.	12.	Clin. Cancer Res. 8: 1 Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "ZI Cancer Res. 62(24): 7:	Antitumor Activity of 974-1983 ascular-targeting action orthotopic tumour cell and Cancer Therapet 'The development of): 1491-1496 D6126: a novel vascu 247-7253	f the Novel Vascular Targetin ivity of ZD6126 against prima I injection in a nude mouse m utics, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause	ary pancrea andel" 14th as a vascu	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of	rowth and lymph node I-AACR Symposium agent" Int J Radiat of tumor vasculature"
/K.C. /K.C.	12.	Clin. Cancer Res. 8: 1 Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "ZI Cancer Res. 62(24): 7: Grosios et al. (2000)	Antitumor Activity of 974-1983 fascular-targeting activity of orthotopic turnour cell and Cancer Therapet The development of 1): 1491-1496 D6126: a novel vascu 247-7253 Combination chemot	f the Novel Vascular Targetin vity of ZD6126 against prima I injection in a nude mouse m tities, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A	ary pancres ary pancres addel" 14th as a vascu as selective	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of	rowth and lymph node I-AACR Symposium agent" Int J Radiat of tumor vasculature"
/K.C. /K.C.	12.	Clin. Cancer Res. 8: 1: Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) " Oncol Biol Phys. 54(5 Davis et al. (2002) "21 Cancer Res. 62(24): 7: Grosios et al. (2000) " experimental murine o Horsman et al. (2000)	Antitumor Activity of 974-1983 ascular-targeting activity of and Cancer Therapet The development of i): 1491-1496 D6126: a novel vascu 247-7253 Combination chemoto colon adenocarcinom "Combretastatins no "Combretastatins no	f the Novel Vascular Targetin ivity of ZD6126 against primi injection in a nude mouse mitos, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a* Anticancer Res. 20: 229-2; vel vascular targeting drugs fevel vascular targeting drugs fevel vel vascular targeting drugs fevel drugs	ary pancres ary pancres andel" 14th as a vascu as selective a-4 phosph 33	D6126 in a P stic turnour g EORTC-NC lar targeting destruction c ate and 5-fluc	rowth and lymph node II-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an
/K.C. /K.C. /K.C.	12. 13. 14. 15.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002)", Grosios et al. (2003) "Grosios et al. (2000)" experimental murine e Horsman et al. (2000) Experimental Medical Li et al. (2002) "Precili et al. (2012) "Precili	Antitumor Activity of 974-1983 ascular-targeting activathotopic tumour cal and Cancer Therapeu The development of 15: 1491-1496 D6126: a novel vascu 247-7253 Combination chemot 2010 a adenocarcinom "Combretastatins no Biology 476: 311-311 inical evaluation of the mincal evaluation of the 374-1983 1994-1995	f the Novel Vascular Targetin ivity of ZD6126 against prima injection in a nude mouse mities, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a' Anticancer Res. 20: 229-22 vel vascular targeting drugs from 220 232 232 233 244 255 256 257 257 257 257 257 257 257 257	ary pancrea sodel" 14th as a vascu as selective a-4 phosph 33 or improvi	D6126 in a P attic turnour g EORTC-NC lar targeting destruction c ate and 5-flue ng anti-cance	rowth and lymph node 1-AACR Symposium agenr" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in oretastatin A-4 disodium
/K.C. /K.C. /K.C. /K.C.	12. 13. 14. 15.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "O ncol Biol Phys. 54(5 Davis et al. (2002) "2 Cancer Res. 62(24): 7. Grosios et al. (2000) Experimental murine o Horsman et al. (2000) Experimental Medical Li et al. (2002) "Precliphosphate and conven	Antitumor Activity of 974-1933 ascular-targeting activitotopic turnour cal and Cancer Therapet The development of pi: 1491-1496 D6126: a novel vascu- 247-7253 Combination chemotolon adenocarcinom "Combretastatins no Biology 476: 311-33 inical evaluation of the titonal anticancer there Enhancement of rad	f the Novel Vascular Targetin vity of ZD6126 against primi linjection in a nude mouse m tiles, Abstract 1118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a*Anticancer Res. 20: 229-2: vel vascular targeting drugs f 23	ary pancrea ary pancrea sodel" 14th as a vascu as selective a-4 phosph 33 or improvi- lar targetin osi's sarcoi	atic turnour g EORTC-NC lar targeting destruction of ate and 5-fluo ng anti-cance g agent comb ma" Acta On	rowth and lymph node II-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in col. 41(1):91-97
/K.C. /K.C. /K.C. /K.C. /K.C./	12. 13. 14. /15. 16.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets on Molecular Copaline at (2002)." Oncol Biol Phys. 54(5 Davis et al. (2002). "Cl Cancer Res. 62(24).". Grosios et al. (2000) "Experimental murine of Horsman et al. (2000) Experimental Medical Li et al. (2002)." Brechiposphate and conven Siemann et al. (2002). Oncol Biol Phys. 33(1 Siemann et al. (2002).	Antitumor Activity of 974-1983 ascular-targeting activithotopic tumour cal and Cancer Therapet The development of 9; 1491-1496 D6126: a novel vascu 247-7253 Combination chemotolon adenocarcinom "Combretastatins no Biology 476: 311-3; inical evaluation of the titonal anticancer ther "Enhancement of rad; 164-167 (a) 1; 164-171	f the Novel Vascular Targetin ivity of ZD6126 against primi I injection in a nude mouse m tics, Abstract 118 combretastatin A4 phosphate alar-targeting agent that cause therapy with combretastatin A a* Anticancer Res. 20: 229-2; vel vascular targeting drugs full 23 24 25 26 27 28 29 29 29 29 29 29 29 29 29 29	ary pancreason Ziary pa	D6126 in a P stic turnour g EORTC-NC lar targeting destruction of ate and 5-fluo ng anti-cance g agent comb ma" Acta One geting agent 2	rowth and lymph node II-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in roctastatin A-4 disodium col. 41(1):91-97 ZD6126" Int J Radiat
/K.C. /K.C. /K.C. /K.C. /K.C./ /K.C./	12. 13. 14. /15. 16. 17.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets Chaplin et al. (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "Zl Cancer Res. 62(24): 7: Grosios et al. (2000) "Experimental Medical Lei et al. (2002) "Precibosphate and convenients of the control of the contro	Antitumor Activity of 974-1983 ascular-targeting activithotopic tumour cal and Cancer Therapet The development of 9: 1491-1496 D6126: a novel vascu 247-7253 combination chemotolon adenocarcinom "Combiratsatins no 18-iology 476: 311-3: inical evaluation of the titional anticancer ther "Enhancement of rad 9: 164-171 "Vascular targeting a	f the Novel Vascular Targetin ivity of ZD6126 against primi injection in a nude mouse mitos, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a" Anticancer Res. 20: 229-22 vel vascular targeting drugs for 23 herapies in the treatment of Kap liation therapy by the novel vi-	ary pancreasode!" 14th as a vascu as selective a-4 phosph 33 or improvi. lar targetin osi's sarcon ascular targetin utic agent a	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of ate and 5-flue ng anti-cance g agent combina" Acta On getting agent 2 activities in se	rowth and lymph node 1-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in oretastatin A-4 disodium col. 41(1):91-97 ZD6126" Int J Radiat
/K.C. /K.C. /K.C. /K.C. /K.C. /K.C. /K.C.	12. 13. 14. 15. 16. 17. 18.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets on Molecular Targets (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "Z Cancer Res. 62(24): 7. Grosios et al. (2000) "Experimental murine of Horsman et al. (2000) Experimental Medical Li et al. (2002) "Brecil phosphate and conven Siemann et al. (2002) Oncol Biol Phys. 53(1 Siemann et al. (2002) J Cancer 99(1): 1-6 Hoope et al. (2003) "I Cancer 99(1): 1-6 Hoope et al. (2003) "	Antitumor Activity of 974-1983 ascular-targeting activithotopic tumour cal and Cancer Therapet The development of 9: 1491-1496 D6126: a novel vascu 247-7253 combination chemotolon adenocarcinom "Combiratsatins no 18-iology 476: 311-3: inical evaluation of the titional anticancer ther "Enhancement of rad 9: 164-171 "Vascular targeting a	f the Novel Vascular Targetin ivity of ZD6126 against primi injection in a nude mouse mitos, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a' Anticancer Res. 20: 229-2; vel vascular targeting drugs for 23 24 25 26 27 28 29 29 29 29 29 29 29 29 29 29	ary pancreasode!" 14th as a vascu as selective a-4 phosph 33 or improvi. lar targetin osi's sarcon ascular targetin utic agent a	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of ate and 5-flue ng anti-cance g agent combina" Acta On getting agent 2 activities in se	rowth and lymph node 1-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in oretastatin A-4 disodium col. 41(1):91-97 ZD6126" Int J Radiat
/K.C. /K.C. /K.C. /K.C. /K.C. /K.C. /K.C.	12. 13. 14. 15. 16. 17. 18.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets on Molecular Targets (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "Z Cancer Res. 62(24): 7. Grosios et al. (2000) "Experimental murine of Horsman et al. (2000) Experimental Medical Li et al. (2002) "Brecil phosphate and conven Siemann et al. (2002) Oncol Biol Phys. 53(1 Siemann et al. (2002) J Cancer 99(1): 1-6 Hoope et al. (2003) "I Cancer 99(1): 1-6 Hoope et al. (2003) "	Antitumor Activity of 974-1983 ascular-targeting activithotopic tumour cal and Cancer Therapet The development of 9: 1491-1496 D6126: a novel vascu 247-7253 combination chemotolon adenocarcinom "Combiratsatins no 18-iology 476: 311-3: inical evaluation of the titional anticancer ther "Enhancement of rad 9: 164-171 "Vascular targeting a	f the Novel Vascular Targetin ivity of ZD6126 against primi injection in a nude mouse mitos, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a' Anticancer Res. 20: 229-2; vel vascular targeting drugs for 23 24 25 26 27 28 29 29 29 29 29 29 29 29 29 29	ary pancreasode!" 14th as a vascu as selective a-4 phosph 33 or improvi. lar targetin osi's sarcon ascular targetin utic agent a	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of ate and 5-flue ng anti-cance g agent combina" Acta On getting agent 2 activities in se	rowth and lymph node 1-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in oretastatin A-4 disodium col. 41(1):91-97 ZD6126" Int J Radiat
/K.C. /K.C. /K.C. /K.C. /K.C. /K.C. /K.C.	12. 13. 14. 15. 16. 17. 18.	Clin. Cancer Res. 8: 1. Bruns et al. (2002) "V metastasis following o on Molecular Targets on Molecular Targets (2002) "Oncol Biol Phys. 54(5 Davis et al. (2002) "Z Cancer Res. 62(24): 7. Grosios et al. (2000) "Experimental murine of Horsman et al. (2000) Experimental Medical Li et al. (2002) "Brecil phosphate and conven Siemann et al. (2002) Oncol Biol Phys. 53(1 Siemann et al. (2002) J Cancer 99(1): 1-6 Hoope et al. (2003) "I Cancer 99(1): 1-6 Hoope et al. (2003) "	Antitumor Activity of 974-1983 ascular-targeting activithotopic tumour cal and Cancer Therapet The development of 9: 1491-1496 D6126: a novel vascu 247-7253 combination chemotolon adenocarcinom "Combiratsatins no 18-iology 476: 311-3: inical evaluation of the titional anticancer ther "Enhancement of rad 9: 164-171 "Vascular targeting a	f the Novel Vascular Targetin ivity of ZD6126 against primi injection in a nude mouse mitos, Abstract 118 combretastatin A4 phosphate ular-targeting agent that cause therapy with combretastatin A a' Anticancer Res. 20: 229-2; vel vascular targeting drugs for 23 24 25 26 27 28 29 29 29 29 29 29 29 29 29 29	ary pancreasode!" 14th as a vascu as selective a-4 phosph 33 or improvi. lar targetin osi's sarcon ascular targetin utic agent a	D6126 in a P atic turnour g EORTC-NC lar targeting destruction of ate and 5-flue ng anti-cance g agent combina" Acta On getting agent 2 activities in se	rowth and lymph node 1-AACR Symposium agent" Int J Radiat of tumor vasculature" orouracil in an r therapy" Advances in oretastatin A-4 disodium col. 41(1):91-97 ZD6126" Int J Radiat

Examiner: | /Kendra Carter/ | Date Considered | O2/18/2009 |

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.